P Wijermans

Summary

Affiliation: The Hague
Country: The Netherlands

Publications

  1. doi request reprint Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
    Pierre Wijermans
    Haga Hospital, Leyweg 275, The Hague, The Netherlands
    J Clin Oncol 28:3160-6. 2010
  2. ncbi request reprint Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
    P W Wijermans
    Department of Haematology, Haga Hospital, Leyenburg, Leyweg 275, 2545 CH The Hague, The Netherlands
    Leuk Res 32:587-91. 2008
  3. ncbi request reprint Epigenetic therapy with decitabine for myelodysplasia and leukemia
    P Wijermans
    Leyenburg Hospital, Department of Haematology, Leyweg 275, 2545 CH, The Hague, The Netherlands
    Future Oncol 1:585-91. 2005
  4. ncbi request reprint An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients
    P W Wijermans
    Department of Haematology, Leyenburg Hospital, The Hague, The Netherlands
    Ann Hematol 84:9-17. 2005
  5. ncbi request reprint Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients
    P Wijermans
    Department of Haematology, Leyenburg Hospital, The Hague, The Netherlands
    J Clin Oncol 18:956-62. 2000
  6. ncbi request reprint Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma
    P F Ypma
    Department of Haematology, HagaZiekenhuis, location Leyenburg, The Hague, The Netherlands
    Neth J Med 64:243-7. 2006
  7. ncbi request reprint The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes
    Joan van den Bosch
    Department of Haematology, Leyenburg Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    Leuk Res 28:785-90. 2004
  8. ncbi request reprint Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands
    B A P Laros-van Gorkom
    Department of Haematology, Haga Hospital, location Leyenburg, The Hague, The Netherlands
    Neth J Med 65:333-8. 2007
  9. ncbi request reprint Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera
    E W Muller
    Department of Internal Medicine, University Hospital Groningen, Leyenburg Hospital, The Hague, The Netherlands
    Br J Haematol 89:313-8. 1995
  10. ncbi request reprint Early response to therapy and survival in multiple myeloma
    C G Schaar
    Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands
    Br J Haematol 125:162-6. 2004

Collaborators

Detail Information

Publications16

  1. doi request reprint Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
    Pierre Wijermans
    Haga Hospital, Leyweg 275, The Hague, The Netherlands
    J Clin Oncol 28:3160-6. 2010
    ..The objective of this study was to investigate the efficacy, toxicity, and effects on quality of life of MP-T...
  2. ncbi request reprint Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
    P W Wijermans
    Department of Haematology, Haga Hospital, Leyenburg, Leyweg 275, 2545 CH The Hague, The Netherlands
    Leuk Res 32:587-91. 2008
    ..These data demonstrate encouraging activity for decitabine in CMML, and suggest that studies in other myeloproliferative diseases may be warranted...
  3. ncbi request reprint Epigenetic therapy with decitabine for myelodysplasia and leukemia
    P Wijermans
    Leyenburg Hospital, Department of Haematology, Leyweg 275, 2545 CH, The Hague, The Netherlands
    Future Oncol 1:585-91. 2005
    ..In this article the authors present an overview of this drug with regard to the chemistry, pharmacokinetics and the data that support its role as the new therapeutic agent in leukemia and myelodysplastic syndrome...
  4. ncbi request reprint An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients
    P W Wijermans
    Department of Haematology, Leyenburg Hospital, The Hague, The Netherlands
    Ann Hematol 84:9-17. 2005
    ..In conclusion, low-dose decitabine is an active drug for the treatment of MDS patients, even for those older than 75 years with bad prognostic characteristics...
  5. ncbi request reprint Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients
    P Wijermans
    Department of Haematology, Leyenburg Hospital, The Hague, The Netherlands
    J Clin Oncol 18:956-62. 2000
    ..We performed a second, multicenter phase II study in a larger group of patients to confirm our findings and to study the toxicity of DAC...
  6. ncbi request reprint Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma
    P F Ypma
    Department of Haematology, HagaZiekenhuis, location Leyenburg, The Hague, The Netherlands
    Neth J Med 64:243-7. 2006
    ..Improvement of the cerebellar syndrome in anti-Tr autoantibody paraneoplastic disease is a rare achievement. Early recognition of the concomitant disorders (anti-Tr autoantibody disease and Hodgkin's lymphoma) is of crucial importance...
  7. ncbi request reprint The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes
    Joan van den Bosch
    Department of Haematology, Leyenburg Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    Leuk Res 28:785-90. 2004
    ..However, platelet response strongly predicted for overall survival (P < 0.0001). 5-Aza-2'-deoxycytidine has a clinically significant, often long lasting, effect on the platelet count in a substantial number of high-risk MDS patients...
  8. ncbi request reprint Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands
    B A P Laros-van Gorkom
    Department of Haematology, Haga Hospital, location Leyenburg, The Hague, The Netherlands
    Neth J Med 65:333-8. 2007
    ..As most important side effect opportunistic infections are mentioned. It is, however, unknown whether these complications often lead to problems in general patient care in the Netherlands...
  9. ncbi request reprint Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera
    E W Muller
    Department of Internal Medicine, University Hospital Groningen, Leyenburg Hospital, The Hague, The Netherlands
    Br J Haematol 89:313-8. 1995
    ..The optimal dose regimen that is well tolerated, relieves pruritus, and offers satisfactory haematological control at the same time remains to be established...
  10. ncbi request reprint Early response to therapy and survival in multiple myeloma
    C G Schaar
    Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands
    Br J Haematol 125:162-6. 2004
    ..As established prognostic parameters (Salmon & Durie stage, serum creatinine, and haemoglobin) also remained prognostically significant, we concluded that early response to MP predicts for survival in MM...
  11. ncbi request reprint Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori
    J van den Bosch
    Department of Hematology, Leyenburg Hospital, The Hague, The Netherlands
    Eur J Haematol 68:187-8. 2002
    ..Afterwards the lymphoma disappeared. The patient is 3 yr later in a persistent complete remission. This is the first known case of the disappearance of a MALT lymphoma of the urinary bladder after treatment with HP eradication therapy...
  12. ncbi request reprint Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
    J A Pitako
    Division of Hematology Oncology, Albert Ludwigs University, Freiburg, Germany
    Ann Hematol 84:25-31. 2005
    ..In conclusion, high-risk MDS patients treated with low-dose decitabine have better survival, and spend comparable time in hospital than patients treated with supportive treatment...
  13. ncbi request reprint Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
    G W van Imhoff
    Department of Hematology, University Medical Center Groningen, 97 RB Groningen, The Netherlands
    Leukemia 19:945-52. 2005
    ..In conclusion, this short up-front high-dose sequential chemotherapy regimen, followed by ASCT is highly effective in adults with BL/BLL with limited bone marrow involvement, but less so in patients with LyLy...
  14. ncbi request reprint [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]
    K L Wu
    Erasmus Medisch Centrum, locatie Dijkzigt, Afd Hematologie, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 146:1445-8. 2002
    ..To determine the efficacy and side effects of thalidomide in the treatment of refractory multiple myeloma...
  15. ncbi request reprint Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
    E Maartense
    Department of Internal Medicine, Reinier de Graaf Gasthuis, Reinier de Graafweg, The Netherlands
    Ann Oncol 13:1275-84. 2002
    ..The influence of age on the outcome of follicular non-Hodgkin's lymphoma (FL) was studied in a population-based non-Hodgkin's lymphoma registry...
  16. ncbi request reprint [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]
    H Lokhorst
    Ned Tijdschr Geneeskd 149:808-13. 2005
    ..All patients should receive long-term bisphosphonates. Erythropoietin may be considered in symptomatic anaemia as well as antibiotic prophylaxis during induction therapy which includes dexamethasone...